Posted 1/10/2012 6:41 AM (GMT 0)
This is from a 2011 Mett-analysis on remission stats with Asacol:
Effi cacy of 5-Aminosalicylates in Ulcerative Colitis:
Systematic Review and Meta-Analysis
Alexander C. Ford , MBChB, MD, MRCP 1 , 2 , Jean-Paul Achkar , MD3 , Khurram J. Khan , MD, FRCPC4 , Sunanda V. Kane , MD, MSPH5 ,
Nicholas J. Talley , MD, PhD6 , John K. Marshall , MD, MSc, FRCPC4 and Paul Moayyedi , BSc, MBChB, PhD, MPH, FRCP, FRCPC4
OBJECTIVES: The effi cacy of 5-aminosalicylic acids (5-ASAs) in ulcerative colitis (UC) has been studied previously
in meta-analyses. However, several randomized controlled trials (RCTs) have been published recently,
and no previous meta-analysis has studied the effect of 5-ASA dosage used.
METHODS: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched (through
December 2010). Eligible trials recruited adults with active or quiescent UC, comparing different
doses of 5-ASAs with themselves or placebo. Dichotomous data were pooled to obtain relative risk
(RR) of failure to achieve remission in active UC, and RR of relapse of disease activity in quiescent
UC, with a 95 % confi dence interval (CI). The number needed to treat (NNT) was calculated from the
reciprocal of the risk difference.
RESULTS: The search identifi ed 3,061 citations, and 37 RCTs were eligible. Of these, 11 compared 5-ASA with
placebo in active UC remission, with the RR of no remission with 5-ASAs of 0.79 (95 % CI 0.73 –
0.85; NNT = 6). Doses of ≥ 2.0 g / day were more effective than < 2.0 g / day for remission (RR = 0.91;
95 % CI 0.85 – 0.98). There were 11 RCTs comparing 5-ASAs with placebo in preventing relapse of
quiescent UC, with the RR of relapse of 0.65 (95 % CI 0.55 – 0.76; NNT = 4). Doses of ≥ 2.0 g / day
appeared more effective than < 2.0 g / day for preventing relapse (RR = 0.79; 95 % CI 0.64 – 0.97).
CONCLUSIONS: 5-ASAs are highly effective for inducing remission and preventing relapse in UC. Evidence suggests
that doses of ≥ 2.0 g / day have greater effi cacy, although doses > 2.5 g / day do not appear to lead to
higher remission rates.
Am J Gastroenterol 2011; 106:601–616; doi: 10.1038/ajg.2011.67; published online 15 March 2011